This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC from the diagnostic colonoscopy and clinical staging (cTMN) is available and are pr e- treatment, and patients who are at average risk of colorectal cancer and who are scheduled for routine colonoscopy examinations.
Arm A: Diagnosed with CRC
Arm B: Undergoing screening with colonoscopy for CRC
Arm A: Undergoing treatment for CRC,
Arm B: Past history of CRC
Prevalent colorectal cancer and people undergoing screening for colorectal cancer
Case-control
Retrospective
Not listed
Development of assay
The primary objective of this study is to optimize and evaluate the performance, including sensitivity and specificity, of the preliminary cfDNA marker panel to detect CRC and APL.
ML Training
A portion of the samples will be used to train the ML algorithms and for assay development activities. Another purpose of the study is to collect samples to be used in Analytical Validation (Assay Verification) and system validation.
Click on the lead sponsor to view all of their trials.
